Angiotech's corporate partner, Boston Scientific, announces completion of clinical trial enrollment for third-generation drug-el
08 Oktober 2008 - 10:28PM
PR Newswire (US)
PERSEUS clinical program to evaluate TAXUS(R) Element(TM) Platinum
Chromium Stent VANCOUVER, Oct. 8 /PRNewswire-FirstCall/ --
Angiotech Pharmaceuticals, Inc. (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP),
a global specialty pharmaceutical and medical device company, today
reported that its corporate partner, Boston Scientific Corporation
(NYSE:BSX), has completed enrollment in the PERSEUS trial, designed
to evaluate the third-generation TAXUS(R) Element(TM)
paclitaxel-eluting coronary stent. The Element Stent platform
features the proprietary Platinum Chromium Alloy, and is designed
to enable thinner struts for increased flexibility, a lower profile
and improved radial strength, recoil and radiopacity. "The new
alloy and stent design of TAXUS Element provides improved
deliverability and visibility, even in patients with complex and
challenging anatomy," said Dean J. Kereiakes, M.D., Medical
Director at the Christ Hospital Heart and Vascular Center and the
Lindner Research Center in Cincinnati, the principal investigator
for the trials. "I am very enthusiastic about the potential the
TAXUS Element Stent offers me to treat a broader range of
patients." Currently the leading drug-eluting stents worldwide,
TAXUS Stent Systems have been evaluated by the industry's most
extensive randomized, controlled clinical trial program, as well as
studied in more than 35,000 real-world patients enrolled in
post-approval registries. The PERSEUS clinical program has enrolled
nearly 1,500 patients at 100 U.S. and international centers since
July 2007, and will compare the TAXUS Element Stent to the
prior-generation TAXUS(R) Express(2)(TM) Stent marketed in the
United States since 2004. "We congratulate our partner, Boston
Scientific, on completing enrollment in this historic and
innovative study," said Dr. William Hunter, President and CEO of
Angiotech. "This is an important milestone and represents another
step towards expanding our paclitaxel franchise into
next-generation stent systems and strengthening our world-class
portfolio of drug-coated devices." The TAXUS Element Stent is an
investigational device and is limited by Federal law to
investigational use only and is not available for sale. Boston
Scientific currently anticipates achieving CE Mark approval for the
European markets in 2009. Cautionary Statement Regarding
Forward-Looking Statements
---------------------------------------------------------
Statements contained in this press release that are not based on
historical fact, including without limitation statements containing
the words "believes," "may," "plans," "will," "estimate,"
"continue," "anticipates," "intends," "expects" and similar
expressions, constitute "forward-looking statements" within the
meaning of the U.S. Private Securities Litigation Reform Act of
1995 and "forward-looking information" within the meaning of
applicable Canadian securities laws. All such statements are made
pursuant to the "safe harbor" provisions of applicable securities
legislation. Forward-looking statements may involve, but are not
limited to, comments with respect to our objectives and priorities
for the second half of 2008 and beyond, our strategies or future
actions, our targets, expectations for our financial condition and
the results of, or outlook for, our operations, research
development and product and drug development. Such forward-looking
statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results, events or developments
to be materially different from any future results, events or
developments expressed or implied by such forward-looking
statements. Many such risks, uncertainties and other factors are
taken into account as part of our assumptions underlying these
forward-looking statements and include, among others, the
following: general economic and business conditions, both
nationally and in the regions in which we operate; market demand;
technological changes that could impact our existing products or
our ability to develop and commercialize future products;
competition; existing governmental regulations and changes in, or
the failure to comply with, governmental regulations; adverse
results or unexpected delays in pre-clinical and clinical product
development processes; adverse findings related to the safety
and/or efficacy of our products or products sold by our partners;
decisions, and the timing of decisions, made by health regulatory
agencies regarding approval of our technology and products; and the
requirement for substantial funding to conduct research and
development and to expand manufacturing and commercialization
activities or consummate acquisitions. In addition, our business is
subject to certain operating risks that may cause any results
expressed or implied by the forward-looking statements in this
press release to differ materially from our actual results. These
operating risks include: our ability to attract and retain
qualified personnel; our ability to successfully complete
pre-clinical and clinical development of our products; changes in
business strategy or development plans; our failure to obtain
patent protection for discoveries; loss of patent protection
resulting from third party challenges to our patents;
commercialization limitations imposed by patents owned or
controlled by third parties; our ability to obtain rights to
technology from licensors; liability for patent claims and other
claims asserted against us; our ability to obtain and enforce
timely patent and other intellectual property protection for our
technology and products; the ability to enter into, and to
maintain, corporate alliances relating to the development and
commercialization of our technology and products; market acceptance
of our technology and products; our ability to successfully
manufacture, market and sell our products; the continued
availability of capital to finance our activities; and any other
factors referenced in our other filings with the Securities and
Exchange Commission (the "SEC"). Given these uncertainties,
assumptions and risk factors, readers are cautioned not to place
undue reliance on such forward-looking statements. Except as
required by law, we disclaim any obligation to update any such
factors or to publicly announce the result of any revisions to any
of the forward-looking statements contained in this press release
to reflect future results, events or developments. Boston
Scientific Corporation acquired worldwide exclusive rights from
Angiotech to use paclitaxel on its coronary stent products and has
co-exclusive rights to certain peripheral vascular and non-vascular
products. TAXUS(R) Element(TM) and Express(2)(TM) are trademarks of
Boston Scientific Corporation. About Angiotech Angiotech
Pharmaceuticals, Inc. is a global specialty pharmaceutical and
medical device company with over 1,500 dedicated employees.
Angiotech discovers, develops and markets innovative treatment
solutions for diseases or complications associated with medical
device implants, surgical interventions and acute injury. To find
out more about Angiotech (NASDAQ:ANPINASDAQ:TSX:NASDAQ:ANP), please
visit our website at http://www.angiotech.com/. DATASOURCE:
Angiotech Pharmaceuticals, Inc. CONTACT: DeDe Sheel, Investor
Relations and Corporate Communications, Angiotech Pharmaceuticals,
Inc., (415) 293-4412,
Copyright
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Angiotech Pharmaceuticals - Common Shares (MM) (NASDAQ:ANPI)
Historical Stock Chart
Von Jul 2023 bis Jul 2024